Rubitecan

Jump to: navigation, search
Rubitecan
File:Rubitecan.png
Clinical data
Routes of
administration
Oral
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H15N3O6
Molar mass393.349 g/mol

WikiDoc Resources for Rubitecan

Articles

Most recent articles on Rubitecan

Most cited articles on Rubitecan

Review articles on Rubitecan

Articles on Rubitecan in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Rubitecan

Images of Rubitecan

Photos of Rubitecan

Podcasts & MP3s on Rubitecan

Videos on Rubitecan

Evidence Based Medicine

Cochrane Collaboration on Rubitecan

Bandolier on Rubitecan

TRIP on Rubitecan

Clinical Trials

Ongoing Trials on Rubitecan at Clinical Trials.gov

Trial results on Rubitecan

Clinical Trials on Rubitecan at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Rubitecan

NICE Guidance on Rubitecan

NHS PRODIGY Guidance

FDA on Rubitecan

CDC on Rubitecan

Books

Books on Rubitecan

News

Rubitecan in the news

Be alerted to news on Rubitecan

News trends on Rubitecan

Commentary

Blogs on Rubitecan

Definitions

Definitions of Rubitecan

Patient Resources / Community

Patient resources on Rubitecan

Discussion groups on Rubitecan

Patient Handouts on Rubitecan

Directions to Hospitals Treating Rubitecan

Risk calculators and risk factors for Rubitecan

Healthcare Provider Resources

Symptoms of Rubitecan

Causes & Risk Factors for Rubitecan

Diagnostic studies for Rubitecan

Treatment of Rubitecan

Continuing Medical Education (CME)

CME Programs on Rubitecan

International

Rubitecan en Espanol

Rubitecan en Francais

Business

Rubitecan in the Marketplace

Patents on Rubitecan

Experimental / Informatics

List of terms related to Rubitecan


Overview

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.

History

On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, [1] and was accepted for filing on March 2004.[2]

On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,[3] and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.[4]

References

  1. "Drugs.com, SuperGen completes submission of New Drug Application (NDA) for Orathecin as an oral treatment for pancreatic cancer". Retrieved 2008-03-25.
  2. "Drugs.com, SuperGen's New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing". Retrieved 2008-03-25.
  3. "Drugs.com, SuperGen Announces Withdrawal of Orathecin NDA". Retrieved 2008-03-25.
  4. "Press release from the EMEA website regarding withdrawal of Orathecin MAA" (PDF). Retrieved 2008-03-25.



Linked-in.jpg